|
1.
|
Rauh-Hain JA, Krivak TC, Del Carmen MG and
Olawaiye AB: Ovarian cancer screening and early detection in the
general population. Rev Obstet Gynecol. 4:15–21. 2011.PubMed/NCBI
|
|
2.
|
Auersperg N, Wong AS, Choi KC, Kang SK and
Leung PC: Ovarian surface epithelium: biology, endocrinology, and
pathology. Endocr Rev. 22:255–288. 2001.PubMed/NCBI
|
|
3.
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
4.
|
Sankaranarayanan R and Ferlay J: Worldwide
burden of gynaecological cancer: the size of the problem. Best
Pract Res Clin Obstet Gynaecol. 20:207–225. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Burger HG, Fuller PJ, Chu S, et al: The
inhibins and ovarian cancer. Mol Cell Endocrinol. 180:145–148.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Jelovac D and Armstrong DK: Recent
progress in the diagnosis and treatment of ovarian cancer. CA
Cancer J Clin. 61:183–203. 2011. View Article : Google Scholar
|
|
7.
|
Jelovac D and Armstrong DK: Role of
farletuzumab in epithelial ovarian carcinoma. Curr Pharm Des.
18:3812–3815. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Van Nagell JR Jr and Pavlik EJ: Ovarian
cancer screening. Clin Obstet Gynecol. 55:43–51. 2012.
|
|
9.
|
Prat J, Ribe A and Gallardo A: Hereditary
ovarian cancer. Hum Pathol. 36:861–870. 2005. View Article : Google Scholar
|
|
10.
|
Turk V, Stoka V and Turk D: Cystatins:
biochemical and structural properties, and medical relevance. Front
Biosci. 13:5406–5420. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Smid L, Strojan P, Budihna M, et al:
Prognostic value of cathepsins B, D and steffins A and B in
laryngeal carcinoma. Eur Arch Otorhinolaryngol. 254(Suppl 1):
S150–S153. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Kos J and Lah TT: Cysteine proteinases and
their endogenous inhibitors: target proteins for prognosis,
diagnosis and therapy in cancer (Review). Oncol Rep. 5:1349–1361.
1998.PubMed/NCBI
|
|
13.
|
Levicar N, Kos J, Blejec A, et al:
Comparison of potential biological markers cathepsin B, cathepsin
L, stefin A and stefin B with urokinase and plasminogen activator
inhibitor-1 and clinicopathological data of breast carcinoma
patients. Cancer Detect Prev. 26:42–49. 2002. View Article : Google Scholar
|
|
14.
|
Zhang R, Tremblay TL, McDermid A, Thibault
P and Stanimirovic D: Identification of differentially expressed
proteins in human glioblastoma cell lines and tumors. Glia.
42:194–208. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Strojan P, Anicin A, Svetic B, Pohar M,
Smid L and Kos J: Stefin A and stefin B: markers for prognosis in
operable squamous cell carcinoma of the head and neck. Int J Radiat
Oncol Biol Phys. 68:1335–1341. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Shiraishi T, Mori M, Tanaka S, Sugimachi K
and Akiyoshi T: Identification of cystatin B in human esophageal
carcinoma, using differential displays in which the gene expression
is related to lymph-node metastasis. Int J Cancer. 79:175–178.
1998. View Article : Google Scholar
|
|
17.
|
Ebert E, Werle B, Julke B, et al:
Expression of cysteine protease inhibitors stefin A, stefin B, and
cystatin C in human lung tumor tissue. Adv Exp Med Biol.
421:259–265. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Ji NY, Kang YH, Park MY, et al:
Development of a fluorescent microsphere immunoassay for cystatin B
(CSTB) in serum of patients with hepatocellular carcinoma. Clin
Chem Lab Med. 49:151–155. 2011.PubMed/NCBI
|
|
19.
|
Kos J, Krasovec M, Cimerman N, Nielsen HJ,
Christensen IJ and Brunner N: Cysteine proteinase inhibitors stefin
A, stefin B, and cystatin C in sera from patients with colorectal
cancer: relation to prognosis. Clin Cancer Res. 6:505–511.
2000.PubMed/NCBI
|
|
20.
|
Mirtti T, Alanen K, Kallajoki M, Rinne A
and Soderstrom KO: Expression of cystatins, high molecular weight
cytokeratin, and proliferation markers in prostatic adenocarcinoma
and hyperplasia. Prostate. 54:290–298. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Massague J: TGFbeta in cancer. Cell.
134:215–230. 2008. View Article : Google Scholar
|
|
22.
|
Nilsson EE and Skinner MK: Role of
transforming growth factor beta in ovarian surface epithelium
biology and ovarian cancer. Reprod Biomed Online. 5:254–258. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Attisano L and Wrana JL: Signal
transduction by the TGF-beta superfamily. Science. 296:1646–1647.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Derynck R, Zhang Y and Feng XH: Smads:
transcriptional activators of TGF-beta responses. Cell. 95:737–740.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Massague J, Seoane J and Wotton D: Smad
transcription factors. Genes Dev. 19:2783–2810. 2005. View Article : Google Scholar
|
|
26.
|
Cardillo MR, Yap E and Castagna G:
Molecular genetic analysis of TGF-beta1 in ovarian neoplasia. J Exp
Clin Cancer Res. 16:49–56. 1997.PubMed/NCBI
|
|
27.
|
Wang D, Kanuma T, Mizunuma H, et al:
Analysis of specific gene mutations in the transforming growth
factor-beta signal transduction pathway in human ovarian cancer.
Cancer Res. 60:4507–4512. 2000.PubMed/NCBI
|
|
28.
|
Berchuck A, Rodriguez G, Olt G, et al:
Regulation of growth of normal ovarian epithelial cells and ovarian
cancer cell lines by transforming growth factor-beta. Am J Obstet
Gynecol. 166:676–684. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Zeng F, Xu G, Zhou T, et al: Reduced
expression of activin receptor-like kinase 7 in breast cancer is
associated with tumor progression. Med Oncol. 29:2519–2526. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Inman GJ, Nicolas FJ, Callahan JF, et al:
SB-431542 is a potent and specific inhibitor of transforming growth
factor-beta superfamily type I activin receptor-like kinase (ALK)
receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 62:65–74. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Lah TT, Kokalj-Kunovar M, Kastelic L, et
al: Cystatins and stefins in ascites fluid from ovarian carcinoma.
Cancer Lett. 61:243–253. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Kastelic L, Turk B, Kopitar-Jerala N, et
al: Stefin B, the major low molecular weight inhibitor in ovarian
carcinoma. Cancer Lett. 82:81–88. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Pennacchio LA, Lehesjoki AE, Stone NE, et
al: Mutations in the gene encoding cystatin B in progressive
myoclonus epilepsy (EPM1). Science. 271:1731–1734. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Kaur G, Mohan P, Pawlik M, et al: Cystatin
C rescues degenerating neurons in a cystatin B-knockout mouse model
of progressive myoclonus epilepsy. Am J Pathol. 177:2256–2267.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Butinar M, Prebanda MT, Rajkovic J, et al:
Stefin B deficiency reduces tumor growth via sensitization of tumor
cells to oxidative stress in a breast cancer model. Oncogene. Aug
19–2013.Epub ahead of print. View Article : Google Scholar
|
|
36.
|
Feldman AS, Banyard J, Wu CL, McDougal WS
and Zetter BR: Cystatin B as a tissue and urinary biomarker of
bladder cancer recurrence and disease progression. Clin Cancer Res.
15:1024–1031. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Gashenko EA, Lebedeva VA, Brak IV,
Tsykalenko EA, Vinokurova GV and Korolenko TA: Evaluation of serum
procathepsin B, cystatin B and cystatin C as possible biomarkers of
ovarian cancer. Int J Circumpolar Health. 72:212152013. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Wong AS and Leung PC: Role of endocrine
and growth factors on the ovarian surface epithelium. J Obstet
Gynaecol Res. 33:3–16. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Akhurst RJ and Derynck R: TGF-beta
signaling in cancer - a double-edged sword. Trends Cell Biol.
11:S44–S51. 2001.PubMed/NCBI
|
|
40.
|
Derynck R, Akhurst RJ and Balmain A:
TGF-beta signaling in tumor suppression and cancer progression. Nat
Genet. 29:117–129. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Lynch MA, Nakashima R, Song H, et al:
Mutational analysis of the transforming growth factor beta receptor
type II gene in human ovarian carcinoma. Cancer Res. 58:4227–4232.
1998.PubMed/NCBI
|
|
42.
|
Chen T, Triplett J, Dehner B, et al:
Transforming growth factor-beta receptor type I gene is frequently
mutated in ovarian carcinomas. Cancer Res. 61:4679–4682.
2001.PubMed/NCBI
|
